Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine

Update Item Information
Title Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine
Creator Mariella C. Pappaterra, BS; Enrique J. Rivera, MD; Armando L. Oliver, MD
Affiliation Department of Ophthalmology, Medical Sciences Campus, University of Puerto Rico, Paseo Dr. Jose Celso Barbosa, San Juan, Puerto Rico
Abstract The first 2 vaccines approved by the United States Food and Drug Administration for emergency use during the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) pandemic were the BNT162b2 vaccine and the messenger RNA-1273 (mRNA-1273) vaccine.
Subject SARSCoV-2; Vaccines
OCR Text Show
Date 2023-03
Date Digital 2023-03
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Source Journal of Neuro-Ophthalmology, March 2023, Volume 43, Issue 1
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s603ngnj
Setname ehsl_novel_jno
ID 2460121
Reference URL https://collections.lib.utah.edu/ark:/87278/s603ngnj
Back to Search Results